Practice-Changing Trial in Second-Line Endometrial Cancer

(MedPage Today) -- A second-line combination of anti-PD-1 immunotherapy plus VEGF inhibition improved survival outcomes compared with single-agent chemotherapy in advanced or metastatic endometrial cancer, the phase III KEYNOTE-775/Study 309 trial...